These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11001383)

  • 1. Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group.
    Gwyther SJ; Nielsen OS; Judson IR; van Glabbeke M; Verweij J
    Anticancer Drugs; 2000 Jul; 11(6):433-7. PubMed ID: 11001383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
    van Oosterom AT; Mouridsen HT; Nielsen OS; Dombernowsky P; Krzemieniecki K; Judson I; Svancarova L; Spooner D; Hermans C; Van Glabbeke M; Verweij J;
    Eur J Cancer; 2002 Dec; 38(18):2397-406. PubMed ID: 12460784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
    J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose ifosfamide in the treatment of advanced soft tissue sarcomas.
    Tursz T
    Semin Oncol; 1996 Jun; 23(3 Suppl 7):34-9. PubMed ID: 8711500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
    Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
    Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of soft-tissue sarcomas: high-dose ifosfamide or combination of ifosfamide and etoposide?
    Yalçin S
    Ann Oncol; 1999 Jan; 10(1):123-4. PubMed ID: 10076733
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
    J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
    Ishii T; Tatezaki S; Satoh T; Yonemoto T; Umeda T; Kitoh M
    Gan To Kagaku Ryoho; 1997 Nov; 24(14):2123-30. PubMed ID: 9388523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
    Demetri GD
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):22-6. PubMed ID: 8677444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
    Nielsen OS; Judson I; van Hoesel Q; le Cesne A; Keizer HJ; Blay JY; van Oosterom A; Radford JA; Svancárová L; Krzemienlecki K; Hermans C; van Glabbeke M; Oosterhuis JW; Verweij J
    Eur J Cancer; 2000 Jan; 36(1):61-7. PubMed ID: 10741296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
    Schütte J; Mouridsen HT; Stewart W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
    Eur J Cancer; 1990; 26(5):558-61. PubMed ID: 2144740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
    Van Glabbeke M; van Oosterom AT; Steward W; Verweij J; Mouridsen H
    Eur J Cancer; 1993; 29A(14):1943-7. PubMed ID: 8280486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.
    Noujaim J; Constantinidou A; Messiou C; Thway K; Miah A; Benson C; Judson I; Jones RL
    Am J Clin Oncol; 2018 Feb; 41(2):147-151. PubMed ID: 26523439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence?
    Verweij J
    Ann Oncol; 1998 Aug; 9(8):807-9. PubMed ID: 9789601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.